Ankylosing Spondylitis Before and After the Anti-TNF Era: A Systematic Review
Main Article Content
Abstract
Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton. The introduction of anti-TNF therapies has significantly improved clinical outcomes in AS patients.
Objective: To systematically review the clinical efficacy of anti-TNF agents in AS, comparing disease activity and functional status before and after treatment.
Methods: A systematic search was conducted across major databases up to January 2021. Studies reporting outcomes before and after anti-TNF treatment using validated measures such as BASDAI, ASAS20, and CRP were included. Data synthesis was performed using random-effects meta-analytic models.
Results: Seventeen studies with a combined sample of over 800 AS patients were included. Anti-TNF therapy resulted in significant reductions in BASDAI scores (mean difference: -2.6), CRP levels, and improvements in ASAS20 response rates. Adalimumab and infliximab demonstrated slightly higher efficacy compared to other agents. Safety profiles were acceptable across studies.
Conclusion: Anti-TNF agents substantially reduce disease activity and improve quality of life in AS patients. However, long-term structural outcomes remain inadequately studied and warrant further investigation.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Mark C Hwang, Lauren Ridley, John D Reveille. Ankylosing spondylitis risk factors: a systematic literature review. Clin Rheumatol. 2021 Mar 22;40(8):3079–3093. doi: 10.1007/s10067-021-05679-7.
3. Yuehan Xiong, Jianmin Zhang et al. The etiology and pathogenesis of ankylosing spondylitis. Front Immunol. 2022 Oct 17; 13:996103. doi: 10.3389/fimmu.2022.996103.
4. Jiapeng Wang a, Lin Yang b et al. Progress in targeted therapy for ankylosing spondylitis: A review, Medicine (Baltimore). 2024 Nov 29;103(48): e40742. doi: 10.1097/ MD.0000000000040742.
5. Parv Agrawal, Sachin Tote, Bhagyesh Sapkale. Diagnosis and Treatment of Ankylosing Spondylitis. Cureus. 2024 Jan 19;16(1):e52559. doi: 10.7759 /cureus.52559
6. Michael H Weisman. Inflammatory Back Pain. Rheum Dis Clin North Am. 2012 Aug;38(3):501–512. doi: 10.1016/j.rdc.2012.09.002.
7. Onecia Benjamin, Amandeep Goyal, Sarah L. Lappin. Disease-Modifying Antirheumatic Drugs (DMARD). StatPearls [Internet], Last Update: July 3, 2023.
8. Johanna Callhoff, Joachim Listing et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015 Jun;74(6):1241-8. doi: 10.1136/ARD-2014-205322. Epub 2014 Apr 9.
9. Weiliang He a, Zixiang Wu a et al. Global research trends in biological therapy for ankylosing spondylitis: A comprehensive visualization and bibliometric study (2004–2023). Hum Vaccin Immunother. 2025 Jan 15;21(1):2445900. doi: 10.1080/ 21645515.2024.2445900
10. Wichor M Bramer, Jos Kleijnen et al. A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc. 2018 Oct 1;106(4):531–541. doi: 10.5195/jmla.2018.283.
11. Ah-Ra Choi, Tae-Jong Kim et al. the effectiveness of tumor necrosis factor-α blocker therapy in patients with axial spondyloarthritis who failed conventional treatment: a comparative study focused on improvement in ASAS Health Index. J Rheum Dis. 2024 Jul 1;31(3):171-177. doi: 10.4078/jrd.2024.0029. Epub 2024 Apr 29.
12. Katarzyna Wiąk-Walerowicz, Ewa Wielosz et al. Comparison of Ankylosing Spondylitis Disease Activity Score and Bath Ankylosing Spondylitis Disease Activity Index tools in assessment of axial spondyloarthritis activity. Reumatologia. 2024 Mar 18;62(1):64–69. doi: 10.5114/reum/185429.
13. Carmen Stolwijk, John D Reveille et al. Epidemiology of Spondyloarthritis. Rheum Dis Clin North Am. 2012 Aug;38(3):441–476. Doi: 10.1016 / j.rdc.2012.09. 003.
14. Kyle J. Wenker, Jessilin M. Quint. Ankylosing Spondylitis. StatPearls [Internet]. Last Update: June 20, 2023.
15. Abdulrahman Alotaibi, Danah Albarrak, Yousef Alammari. The Efficacy and Safety of Biologics in Treating Ankylosing Spondylitis and Their Impact on Quality of Life and Comorbidities: A Literature Review. Cureus. 2024 Mar 3;16(3): e55459. doi: 10.7759/cureus.55459.
16. Bui Hai Binh, Le-Thi Bich Phuong et al. Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors. Mater Sociomed. 2023;35(3):222–227. doi: 10.5455/msm.2023.35.222-227.
17. Desirée Ruiz-Vilchez, Clementina López-Medina et al. The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis. Ther Adv Musculoskelet Dis. 2024 Sep 5;16:1759720X241272947. doi: 10.1177/1759720X241272947.